Long-Term Analysis of the IFM 99 Trials for Myeloma: Cytogenetic Abnormalities [t(4;14), del(17p), 1q gains] Play a Major Role in Defining Long-Term Survival
Long-Term Analysis of the IFM 99 Trials for Myeloma: Cytogenetic Abnormalities [t(4;14), del(17p), 1q gains] Play a Major Role in Defining Long-Term Survival
复制标题
DOI：
10.1200/jco.2011.36.5726
复制
发表时间：
2012-06-01
影响因子：
45.3
通讯作者：
Moreau, Philippe
中科院分区：
文献类型：
--
作者：
Avet-Loiseau, Herve;Attal, Michel;Moreau, Philippe
目的多发性骨髓瘤的预后参数有很多。然而，所有这些都预示着较短的生存期。为了确定一个较长的预期寿命的患者，我们更新了IFM（Intergroupe法语杜骨髓）99-02和99-04 trials.Patients和MethodsA系列的520例患者进行了分析。中位随访时间为90.5个月。要进行综合分析的主要预后因素，我们重新分析所有患者的1 Q增益[除了更新del（13），t（4; 14），和del（17 p）分析]。ResultsIt是可能的，以确定一个亚组的患者（占总患者的20%），8年生存率为75%。这些患者被定义为缺乏t（4; 14），del（17 p），和1 q增益和β（2）-微球蛋白小于5.5 mg/L。ConclusionWe建议，所有新诊断的多发性骨髓瘤患者进行评估这三个染色体变化，不仅定义高危患者，但也确定那些具有较长的预期寿命。
PurposeIn multiple myeloma, many prognostic parameters have been proposed. However, all of these predict shorter survival. To identify patients with a longer life expectancy, we updated the data of patients treated in the IFM (Intergroupe Francophone du Myelome) 99-02 and 99-04 trials.Patients and MethodsA series of 520 patients was analyzed. Median follow-up was 90.5 months. To perform a comprehensive analysis of the major prognostic factors, we reanalyzed all patients for 1q gains [in addition to updating del(13), t(4; 14), and del(17p) analyses].ResultsIt was possible to identify a subgroup of patients (representing 20% of total patients) with an 8-year survival of 75%. These patients were defined by the absence of t(4; 14), del(17p), and 1q gain and beta(2)-microglobulin less than 5.5 mg/L.ConclusionWe propose that all patients with newly diagnosed multiple myeloma be evaluated for these three chromosomal changes, not only to define high-risk patients but also to identify those with a longer life expectancy.